Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
- 1 September 2021
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 80 (3) , 319-322
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Associazione Italiana per la Ricerca sul Cancro
This publication has 15 references indexed in Scilit:
- Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer PatientsEuropean Urology Oncology, 2020
- Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 TrialEuropean Urology, 2020
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant HistologiesEuropean Urology, 2020
- The effect of antibiotics on the composition of the intestinal microbiota - a systematic reviewJournal of Infection, 2019
- Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With CancerJAMA Oncology, 2019
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialNature Medicine, 2019
- Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell CarcinomaEuropean Urology Oncology, 2019
- The microbiome, cancer, and cancer therapyNature Medicine, 2019
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancerAnnals of Oncology, 2018
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of CyclophosphamideScience, 2013